메뉴 건너뛰기




Volumn 54, Issue 9, 2013, Pages 2568-2572

Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation

Author keywords

CYP3A activity; End stage renal disease; Plasma; Renal failure

Indexed keywords

4BETA HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; CREATININE; CYTOCHROME P450 3A; UNCLASSIFIED DRUG;

EID: 84883160692     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P040022     Document Type: Article
Times cited : (15)

References (40)
  • 1
    • 0029082781 scopus 로고
    • Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy
    • Uchida, N., N. Kurata, K. Shimada, Y. Nishimura, K. Yasuda, M. Hashimoto, E. Uchida, and H. Yasuhara. 1995. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn. J. Pharmacol. 68: 431-439.
    • (1995) Jpn. J. Pharmacol , vol.68 , pp. 431-439
    • Uchida, N.1    Kurata, N.2    Shimada, K.3    Nishimura, Y.4    Yasuda, K.5    Hashimoto, M.6    Uchida, E.7    Yasuhara, H.8
  • 2
  • 4
    • 0142074311 scopus 로고    scopus 로고
    • Down-regulation of hepatic CYP3A in chronic renal insufficiency
    • Rege, B., R. Krieg, N. Gao, and M. A. Sarkar. 2003. Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm. Res. 20: 1600-1606.
    • (2003) Pharm. Res , vol.20 , pp. 1600-1606
    • Rege, B.1    Krieg, R.2    Gao, N.3    Sarkar, M.A.4
  • 6
    • 84857994282 scopus 로고    scopus 로고
    • Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure
    • Kusaba, J., N. Kajikawa, H. Kawasaki, Y. Kurosaki, and T. Aiba. 2012. Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure. Biopharm. Drug Dispos. 33: 22-29.
    • (2012) Biopharm. Drug Dispos , vol.33 , pp. 22-29
    • Kusaba, J.1    Kajikawa, N.2    Kawasaki, H.3    Kurosaki, Y.4    Aiba, T.5
  • 8
    • 67649360564 scopus 로고    scopus 로고
    • Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients
    • Kirwan, C. J., T. Lee, D. W. Holt, R. M. Grounds, I. A. MacPhee, and B. J. Philips. 2009. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med. 35: 1271-1275.
    • (2009) Intensive Care Med , vol.35 , pp. 1271-1275
    • Kirwan, C.J.1    Lee, T.2    Holt, D.W.3    Grounds, R.M.4    Macphee, I.A.5    Philips, B.J.6
  • 9
    • 84859927163 scopus 로고    scopus 로고
    • Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients
    • Kirwan, C. J., I. A. MacPhee, T. Lee, D. W. Holt, and B. J. Philips. 2012. Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med. 38: 76-84.
    • (2012) Intensive Care Med , vol.38 , pp. 76-84
    • Kirwan, C.J.1    Macphee, I.A.2    Lee, T.3    Holt, D.W.4    Philips, B.J.5
  • 10
    • 0036897793 scopus 로고    scopus 로고
    • Down-regulation of hepatic cytochrome p450 in chronic renal failure: Role of uremic mediators
    • Guévin, C., J. Michaud, J. Naud, F. A. Leblond, and V. Pichette. 2002. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br. J. Pharmacol. 137: 1039-1046.
    • (2002) Br. J. Pharmacol , vol.137 , pp. 1039-1046
    • Guévin, C.1    Michaud, J.2    Naud, J.3    Leblond, F.A.4    Pichette, V.5
  • 11
    • 33746364150 scopus 로고    scopus 로고
    • Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes
    • Hanada, K., R. Ogawa, K. Son, Y. Sasaki, A. Kikkawa, S. Ichihara, and H. Ogata. 2006. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron. Physiol. 103: 179-186.
    • (2006) Nephron. Physiol , vol.103 , pp. 179-186
    • Hanada, K.1    Ogawa, R.2    Son, K.3    Sasaki, Y.4    Kikkawa, A.5    Ichihara, S.6    Ogata, H.7
  • 15
    • 0034007388 scopus 로고    scopus 로고
    • Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes
    • Streetman, D. S., J. S. Jr. Bertino, and A. N. Nafziger. 2000. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 10: 187-216.
    • (2000) Pharmacogenetics , vol.10 , pp. 187-216
    • Streetman, D.S.1    Bertino Jr., J.S.2    Nafziger, A.N.3
  • 16
    • 0026341491 scopus 로고
    • Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: A preliminary study
    • Karayalçin, U., Y. Takeda, I. Miyamori, T. Morise, and R. Takeda. 1991. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: a preliminary study. Steroids. 56: 598-600.
    • (1991) Steroids , vol.56 , pp. 598-600
    • Karayalçin, U.1    Takeda, Y.2    Miyamori, I.3    Morise, T.4    Takeda, R.5
  • 17
    • 0347361482 scopus 로고    scopus 로고
    • Urinary 6beta-hydroxycortisol: A validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
    • Galteau, M. M., and F. Shamsa. 2003. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. 59: 713-733.
    • (2003) Eur. J. Clin. Pharmacol , vol.59 , pp. 713-733
    • Galteau, M.M.1    Shamsa, F.2
  • 18
    • 0035914368 scopus 로고    scopus 로고
    • Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome p450 3A4
    • Bodin, K., L. Bretillon, Y. Aden, L. Bertilsson, U. Broomé, C. Einarsson, and U. Diczfalusy. 2001. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J. Biol. Chem. 276: 38685-38689.
    • (2001) J. Biol. Chem , vol.276 , pp. 38685-38689
    • Bodin, K.1    Bretillon, L.2    Aden, Y.3    Bertilsson, L.4    Broomé, U.5    Einarsson, C.6    Diczfalusy, U.7
  • 19
    • 42149130238 scopus 로고    scopus 로고
    • Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy
    • Wide, K., H. Larsson, L. Bertilsson, and U. Diczfalusy. 2008. Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br. J. Clin. Pharmacol. 65: 708-715.
    • (2008) Br. J. Clin. Pharmacol , vol.65 , pp. 708-715
    • Wide, K.1    Larsson, H.2    Bertilsson, L.3    Diczfalusy, U.4
  • 21
    • 58149129621 scopus 로고    scopus 로고
    • 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin
    • Diczfalusy, U., K. P. Kanebratt, E. Bredberg, T. B. Andersson, Y. Böttiger, and L. Bertilsson. 2009. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br. J. Clin. Pharmacol. 67: 38-43.
    • (2009) Br. J. Clin. Pharmacol , vol.67 , pp. 38-43
    • Diczfalusy, U.1    Kanebratt, K.P.2    Bredberg, E.3    Andersson, T.B.4    Böttiger, Y.5    Bertilsson, L.6
  • 25
    • 40049103597 scopus 로고    scopus 로고
    • 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
    • Diczfalusy, U., J. Miura, H. K. Roh, R. A. Mirghani, J. Sayi, H. Larsson, K. G. Bodin, A. Allqvist, M. Jande, J. W. Kim, et al. 2008. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics. 18: 201-208.
    • (2008) Pharmacogenet. Genomics , vol.18 , pp. 201-208
    • Diczfalusy, U.1    Miura, J.2    Roh, H.K.3    Mirghani, R.A.4    Sayi, J.5    Larsson, H.6    Bodin, K.G.7    Allqvist, A.8    Jande, M.9    Kim, J.W.10
  • 28
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft, D.W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron. 16: 31-41.
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 29
    • 79956084944 scopus 로고    scopus 로고
    • A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4 - -hydroxycholesterol in human plasma
    • van de Merbel, N. C., K. J. Bronsema, M. W. van Hout, R. Nilsson, and H. Sillén. 2011. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4 - -hydroxycholesterol in human plasma. J. Pharm. Biomed. Anal. 55: 1089-1095.
    • (2011) J. Pharm. Biomed. Anal , vol.55 , pp. 1089-1095
    • Van De Merbel, N.C.1    Bronsema, K.J.2    Van Hout, M.W.3    Nilsson, R.4    Sillén, H.5
  • 31
    • 0142150027 scopus 로고    scopus 로고
    • Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans
    • Furuta, T., A. Suzuki, C. Mori, H. Shibasaki, A. Yokokawa, and Y. Kasuya. 2003. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab. Dispos. 31: 1283-1287.
    • (2003) Drug Metab. Dispos , vol.31 , pp. 1283-1287
    • Furuta, T.1    Suzuki, A.2    Mori, C.3    Shibasaki, H.4    Yokokawa, A.5    Kasuya, Y.6
  • 32
    • 0031868142 scopus 로고    scopus 로고
    • Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations
    • Kovacs, S. J., D. E. Martin, D. E. Everitt, S. D. Patterson, and D. K. Jorkasky. 1998. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin. Pharmacol. Ther. 63: 617-622.
    • (1998) Clin. Pharmacol. Ther , vol.63 , pp. 617-622
    • Kovacs, S.J.1    Martin, D.E.2    Everitt, D.E.3    Patterson, S.D.4    Jorkasky, D.K.5
  • 36
    • 0034649068 scopus 로고    scopus 로고
    • Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients
    • Strehlau, J., L. Pape, G. Offner, B. Nashan, and J. H. Ehrich. 2000. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet. 356: 1327-1328.
    • (2000) Lancet , vol.356 , pp. 1327-1328
    • Strehlau, J.1    Pape, L.2    Offner, G.3    Nashan, B.4    Ehrich, J.H.5
  • 37
    • 0035993387 scopus 로고    scopus 로고
    • Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients
    • Sifontis, N. M., E. Benedetti, and E. M. Vasquez. 2002. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant. Proc. 34: 1730-1732.
    • (2002) Transplant. Proc , vol.34 , pp. 1730-1732
    • Sifontis, N.M.1    Benedetti, E.2    Vasquez, E.M.3
  • 38
    • 0036456710 scopus 로고    scopus 로고
    • In vitro effects of tacrolimus on human cytochrome P450
    • Lecointre, K., V. Furlan, and A. M. Taburet. 2002. In vitro effects of tacrolimus on human cytochrome P450. Fundam. Clin. Pharmacol. 16: 455-460.
    • (2002) Fundam. Clin. Pharmacol , vol.16 , pp. 455-460
    • Lecointre, K.1    Furlan, V.2    Taburet, A.M.3
  • 39
    • 40349108431 scopus 로고    scopus 로고
    • No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients
    • Kagaya, H., M. Miura, S. Satoh, K. Inoue, M. Saito, T. Inoue, T. Habuchi, and T. Suzuki. 2008. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. J. Clin. Pharm. Ther. 33: 193-201.
    • (2008) J. Clin. Pharm. Ther , vol.33 , pp. 193-201
    • Kagaya, H.1    Miura, M.2    Satoh, S.3    Inoue, K.4    Saito, M.5    Inoue, T.6    Habuchi, T.7    Suzuki, T.8
  • 40
    • 5644239801 scopus 로고    scopus 로고
    • Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats
    • Konishi, H., M. Sumi, N. Shibata, K. Takada, T. Minouchi, and A. Yamaji. 2004. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J. Pharm. Pharmacol. 56: 1259-1266.
    • (2004) J. Pharm. Pharmacol , vol.56 , pp. 1259-1266
    • Konishi, H.1    Sumi, M.2    Shibata, N.3    Takada, K.4    Minouchi, T.5    Yamaji, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.